iBio, Inc. (IBIO)
| Market Cap | 1.92M |
| Revenue (ttm) | 50,000 |
| Net Income (ttm) | -52.63M |
| Shares Out | 1.41M |
| EPS (ttm) | -79.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,318 |
| Open | 1.46 |
| Previous Close | 1.42 |
| Day's Range | 1.35 - 1.46 |
| 52-Week Range | 1.16 - 52.00 |
| Beta | -3.31 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Feb 13, 2024 |
About IBIO
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers;... [Read more]
Financial Performance
Financial StatementsNews
iBio Amends and Extends Maturity of Credit Agreement
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (N...
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000...
iBio Announces Reverse Stock Split
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the ...
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -
iBio Explains Recent Filing of Registration Statement
– No new securities are being registered under the Post-Effective Amendment – – No new securities are being registered under the Post-Effective Amendment –
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the fili...
iBio Announces Amendment to Credit Agreement with Woodforest
– Extends maturity date to December 31, 2023 – – Allows time to close pending sale of CDMO facility – BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or ...
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets –
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth
– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...
iBio Forges Research Collaboration with the National Institutes of Health
– NIH to evaluate iBio's patented AI-driven epitope steering platform for Lassa fever vaccine development –
iBio to Participate in the JMP Securities Life Sciences Conference
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its I...
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given to...
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
– Immuno-oncology candidate discovered using iBio's AI epitope steering platform –
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
- Company has directed antibodies against a specific region of MUC16 -
iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its pre...
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its pre...
iBio Announces Proposed Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer an...
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two pos...
iBio Announces CEO Departure
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors ...
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastP...
iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline
– Positions Company for leadership in AI-powered drug discovery –
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming ® Manufa...
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPhar...
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPh...
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufac...